Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVITAA-ALZ
NCT07756294Phase 2Not yet recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Nov 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
A Phase 2 trial of Generex Oral-lyn, empagliflozin in Alzheimer's disease (AD), sponsored by Wake Forest University Health Sciences. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
Generex Oral-lynempagliflozin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07756294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07756294.